Skip to main content

Table 2 Cox analysis of factors associated with treatment time to remission

From: Significance of serum and pathological biomarkers in fertility-sparing treatment for endometrial cancer or atypical hyperplasia: a retrospective cohort study

  

Univariate analysis

Multivariate analysis

OR (95% CI)

p-value

OR (95% CI)

p-value

BMI (kg/m2)

 ≥ 25

0.717 (0.406–1.268)

0.253

  
 

 < 25

1

   

Age

 ≥ 30

0.544 (0.286–1.032)

0.063

 

 < 30

1

   

Pathology

EAH

2.120 (1.186–3.789)

0.011

3.870 (1.175–12.742)

0.026

 

EC

1

 

1

 

T2DM

Yes

0.816 (0.427–1.957)

0.914

  
 

No

1

   

PCOS

Yes

0.916 (0.476–1.764)

0.793

  
 

No

1

   

Hypothyroidism

Yes

1.842 (0.868–3.908)

0.111

  
 

No

1

   

Metformin

Yes

0.626 (0.324–1.210)

0.164

  
 

No

1

   

HOMA-IR

 ≥ 2.5

0.440 (0.210–0.921)

0.029

0.206 (0.056–0.755)

0.017

 

 < 2.5

1

 

1

 

T0-ER

 

1.461 (0.676–3.158)

0.335

  

T0-PR

 

1.198 (0.651–2.205)

0.561

  

T0-PRB

 

2.560 (0.676–9.695)

0.167

  

T1 vs. T0-ER*

 ≥ 0

1.397 (0.599–3.256)

0.439

  
 

 < 0

1

   

T1 vs. T0-PR*

 ≥ 60%

1.223 (0.504–2.971)

0.656

  
 

 < 60%

1

   

T1 vs. T0-PRB*

 ≥ 30%

2.995 (1.201–7.469)

0.019

5.788 (1.531–21.889)

0.010

 

 < 30%

1

 

1

 

T0-Ki67

 

1.002 (0.986–1.018)

0.826

  
  1. Bold part represents p-value less than or near 0.05
  2. *Defined as the range of reduction at the second assessment compared to the baseline level. OR: odds ratio; CI, confidence interval; EC, endometrial cancer; EAH, endometrial atypical hyperplasia; BMI, body mass index; T2DM, type 2 diabetes mellitus; PCOS, polycystic ovary syndrome